罗格列酮治疗非乙醇性脂肪肝的疗效与脂联素相关

目的:寻找有效、安全、简便治疗非乙醇性脂肪肝的方法及预测疗效的指标.方法:非乙醇性脂肪肝患者(除外肝硬化期)124例随机分为罗格列酮治疗组(n=63)和安慰剂对照组(n=61),比较两组的疗效及对血清脂联素的影响.结果:罗格列酮组对肝功能、血糖、血脂、胰岛素抵抗(HOMA-IR)、血清脂联素的改善优于对照组(P<0.01);总有效率罗格列酮组与对照组比较有显著差异(57/63vs37/61,P<0.01);ALT与脂联素水平负相关正相关(r=-0.685,P<0.01),与HOMA-IR呈正相关(r=0.447,P<0.01).两组在安全性上无差异(P>0.05).结论:罗格列酮是一安全、有效、简便的治疗非乙醇性脂肪肝的药物.血清脂联素水平可作为预测治疗非乙醇性脂肪肝效果的指标.

Efficacy of rosiglitazone in treatment of nonalcoholic fatty liver disease and its relations with adiponectin

AIM: To explore an effective, safe and convenient method in the treatment of nonalcoholic fatty liver disease (NAFLD) and a marker in the pre- diction of the efficacy. METHODS: One hundred and twenty-four pa- tients diagnosed with NAFLD (except cirrhosis) were randomly divided into rosiglitazone (RSG) treatment group and placebo group (controls). After treatment with the corresponding meth- ods, comparative analysis on the efficacy and serum adiponectin was performed between the two groups. RESULTS: ESG significantly improved the liver function, levels of blood glucose, lipid and se- rum adiponectin, as well as insulin resistance (HOMA-IR) (P < 0.05). The total effective rates were markedly significantly between RSG group and placebo group (57/63 vs 37/61, P < 0.01). The levels of serum alanine aminotransferase (ALT) was significantly correlated with adipo-nectin level (r = -0.685, P < 0.01) and HOMA-IR (r = 0.447, P < 0.01). The safety was not notably different between the two groups (P > 0.05). CONCLUSION: RSG is effective and safe in the treatment of NAFLD and serum adiponectin level can be used to predict its efficacy.